(Q34767513)

4 August 2017

1 reference

title

Efficacy and economics of hormonal therapies for advanced breast cancer (English)

1 reference

4 August 2017

Michael S Simon

1

1 reference

4 August 2017

Dina Ibrahim

series ordinal

2

1 reference

4 August 2017

Lisa Newman

series ordinal

3

1 reference

4 August 2017

Miron Stano

series ordinal

4

1 reference

4 August 2017

publication date

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

19

1 reference

4 August 2017

issue

6

1 reference

4 August 2017

page(s)

453-463

1 reference

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

4 August 2017

cites work

1 reference

12 December 2020

Should clinicians be concerned about the carcinogenic potential of tamoxifen?

1 reference

12 December 2020

The economic potential of tamoxifen prophylaxis in breast cancer

1 reference

12 December 2020

Racial differences in breast carcinoma survival

1 reference

12 December 2020

Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model

1 reference

12 December 2020

Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

1 reference

12 December 2020

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

12 December 2020

A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer

1 reference

12 December 2020

Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial

1 reference

12 December 2020

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

1 reference

12 December 2020

The effect of tamoxifen on the endometrium.

1 reference

12 December 2020

Comprehensive pharmacology and clinical efficacy of aromatase inhibitors

1 reference

12 December 2020

Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women

1 reference

12 December 2020

Antithrombin III Level, Fibrinogen Level, and Platelet Count Changes With Adjuvant Tamoxifen Therapy

1 reference

12 December 2020

Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results

1 reference

12 December 2020

Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer?

1 reference

12 December 2020

Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects

1 reference

12 December 2020

Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years

1 reference

12 December 2020

The cost of breast cancer recurrences

1 reference

12 December 2020

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study

1 reference

12 December 2020

Cost of care for cancer in a health maintenance organization

1 reference

12 December 2020

Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels

1 reference

12 December 2020

Safety assessment of tamoxifen and toremifene

1 reference

12 December 2020

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

1 reference

12 December 2020

The costs of cancer to a major employer in the United States: a case-control analysis.

1 reference

12 December 2020

Advanced breast cancer: use of resources and cost implications

1 reference

12 December 2020

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

12 December 2020

Selective estrogen receptor modulators: a look ahead

1 reference

12 December 2020

Counting the costs of cancer therapy

1 reference

12 December 2020

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

12 December 2020

Clinical pharmacology of selective estrogen receptor modulators

1 reference

12 December 2020

Toremifene in postmenopausal breast cancer. Efficacy, safety and cost

1 reference

12 December 2020

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group

1 reference

12 December 2020

The costs of treating breast cancer in Australia and the implications for breast cancer screening

1 reference

12 December 2020

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

12 December 2020

Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients

1 reference

12 December 2020

Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients

1 reference

12 December 2020

Suicide enzyme inhibitors as potential drugs

1 reference

12 December 2020

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

1 reference

12 December 2020

Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women

1 reference

12 December 2020

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer

1 reference

12 December 2020

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

12 December 2020

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

1 reference

12 December 2020

The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer

1 reference

12 December 2020

Efficacy of tamoxifen as treatment of breast cancer

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

12 December 2020

Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation

1 reference

12 December 2020

Declining cancer rates in the 1990s

1 reference

12 December 2020

New endocrine therapies for breast cancer

1 reference

12 December 2020

The biology of breast cancer in older women

1 reference

12 December 2020

Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer

1 reference

12 December 2020

Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.

1 reference

12 December 2020

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

12 December 2020

Breast cancer therapies in development. A review of their pharmacology and clinical potential.

1 reference

12 December 2020

Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996

1 reference

12 December 2020

Advanced breast cancer and its prevention by screening

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Tamoxifen-induced steatohepatitis

1 reference

12 December 2020

Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.

1 reference

12 December 2020

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

12 December 2020

High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment

1 reference

12 December 2020

Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment.

1 reference

12 December 2020

Systemic therapy for older women with breast cancer.

1 reference

12 December 2020

Tamoxifen therapy for breast cancer and endometrial cancer risk.

1 reference

12 December 2020

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

12 December 2020

Estimating the treatment costs of breast and lung cancer

1 reference

12 December 2020

Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women

1 reference

12 December 2020

Reducing the risk of breast cancer

1 reference

12 December 2020

Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care

1 reference

12 December 2020

Diethylstilbestrol revisited in advanced breast cancer management.

1 reference

12 December 2020

Comparison between the Effects of Tamoxifen and Toremifene on the Uterus in Postmenopausal Breast Cancer Patients

1 reference

12 December 2020

Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project

1 reference

12 December 2020

The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis

1 reference

12 December 2020

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene

1 reference

12 December 2020

Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome

1 reference

12 December 2020

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

12 December 2020

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer

1 reference

12 December 2020

10.2165/00002512-200219060-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1014657921

0 references

1 reference